2016

VEGF Trap In Combination With Radiotherapy Improves Tumor Control In U87 Glioblastoma

Phyllis Wachsberger, PhD  
*Thomas Jefferson University, phyllis.wachsberger@jefferson.edu*

Randy Burd, PhD  
*Department of Nutritional Sciences, University of Arizona, Tuscon AZ*

Chris Cardi, MS  
*Department of Radiology, Thomas Jefferson University, chris.cardi@jefferson.edu*

Mathew L. Thakur  
*Thomas Jefferson University, mathew.thakur@jefferson.edu*

Constantine Daskalakis  
*Thomas Jefferson University, Constantine.Daskalakis@jefferson.edu*

*See next page for additional authors*

Follow this and additional works at: [http://jdc.jefferson.edu/bodinejournal](http://jdc.jefferson.edu/bodinejournal)

Part of the [Oncology Commons](http://jdc.jefferson.edu/bodinejournal)

Let us know how access to this document benefits you

**Recommended Citation**

Wachsberger, PhD, Phyllis; Burd, PhD, Randy; Cardi, MS, Chris; Thakur, Mathew L.; Daskalakis, Constantine; Holash, PhD, Jocelyn; Yancopoulos, PhD, George D.; and Dicker, Adam MD, PhD (2016) "VEGF Trap In Combination With Radiotherapy Improves Tumor Control In U87 Glioblastoma," *Bodine Journal*: Vol. 1: Iss. 1, Article 4.  
Available at: [http://jdc.jefferson.edu/bodinejournal/vol1/iss1/4](http://jdc.jefferson.edu/bodinejournal/vol1/iss1/4)

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University’s Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Bodine Journal by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.
VEGF Trap In Combination With Radiotherapy Improves Tumor Control In U87 Glioblastoma

Authors
Phyllis Wachsberger, PhD; Randy Burd, PhD; Chris Cardi, MS; Mathew L. Thakur; Constantine Daskalakis; Jocelyn Holash, PhD; George D. Yancopoulos, PhD; and Adam Dicker MD, PhD
VEGF Trap In Combination With Radiotherapy Improves Tumor Control In U87 Glioblastoma

Phyllis R. Wachsmberger, PhD,* Randy Burd, PhD,† Chris Cardi, MS,† Matthew Thakur, PhD,‡ Constantin Daskalakis, ScD,§ Jocelyn Holash, PhD,* George D. Yancopoulos, PhD,* And Adam P. Dicker, MD, PhD,*

Departments of *Radiation Oncology, †Radiology, ‡Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, PA; †Department of Nutritional Sciences, University of Arizona, Tucson, AZ; and ¶Novartis, Emeryville, CA

The following article is reprinted with permission from Elsevier Inc. It was originally published in the Int. J. Radiation Oncol. Biol. Physics, Volume 67, Issue 5, pages 1526-1537, 2007.

Purpose
To determine the effect of vascular endothelial growth factor VEGF Trap (Regeneron Pharmaceuticals, Tarrytown, NY), a humanized soluble vascular endothelial growth factor (VEGF) receptor protein, and radiation (RT) on tumor growth in U87 glioblastoma xenografts in nude mice.

Methods and Materials
U87 cell suspensions were implanted subcutaneously into hind limbs of nude mice. VEGF Trap (2.5–25 mg/kg) was administered every 3 days for 3 weeks alone or in combination with a single dose of 10 Gy or fractionated RT (3 x 5 Gy). In addition, three scheduling protocols for VEGF Trap plus fractionated RT were examined.

Results
Improved tumor control was seen when RT (either single dose or fractionated doses) was combined with the lowest dose of VEGF Trap (2.5 mg/kg). Scheduling did not significantly affect the efficacy of combined therapy. Although high-dose VEGF Trap alone (10 mg/kg or 25 mg/kg) significantly reduced tumor growth over that of RT alone, there was no additional benefit to combining high-dose VEGF Trap with RT.

Conclusions
VEGF endothelial growth factor Trap plus radiation is clearly better than radiation alone in a U87 subcutaneous xenograft model. Although high doses of VEGF Trap alone are highly efficacious, it is unclear whether such high doses can be used clinically without incurring normal tissue toxicities. Thus, information on lower doses of VEGF Trap and ionizing radiation is of clinical relevance. © 2007 Elsevier Inc.

Key Words: Vascular endothelial growth factor Trap, Radiotherapy, Anti-angiogenic, U87 glioblastoma.

Introduction
Radiation (RT) therapy is an important treatment modality for many cancers; however, its therapeutic success is impeded by dose-limiting normal tissue toxicities and the development of radioresistance. Recent studies emphasize the importance of the tumor microvascular response in addition to the tumor cell response in determining tumor radioresistance. In opposition to endothelial cell damage, radiation also induces signal transduction cascades, which contribute to radiation resistance through upregulation of proliferative, survival, and angiogenic pathways. In particular, radiation induces vascular cytokines, such as vascular endothelial growth factor (VEGF), one of the most potent endothelial cell survival factors, which functions as a powerful antiapoptotic factor for endothelial cells in new blood vessels. Radiation-induced VEGF results in tumor radioresistance through vascular radiosensitization.

Inhibition of VEGF activity or disabling the function of VEGF receptors is therefore a potential strategy for improving radiation outcome. The VEGF blockade alone has been shown to inhibit both tumor growth and metastasis in a variety of animal tumor models. Currently, three approaches are in clinical development to target the VEGF/VEGFR-signaling pathway: (1) monoclonal antibodies directed against VEGF or its receptors, which selectively inhibit VEGF activity; (2) small molecule inhibitors of the VEGFR-2 tyrosine kinase enzymes, and (3) soluble decoy receptors created from the VEGFRI receptor which selectively inhibit VEGF signaling.

The relative benefits of these strategies have yet to be determined clinically.

Tumor cures are rare when VEGF blockers are used as the sole method of treatment; in general, antiangiogenics appear to work best in combination with cytotoxic therapies. A number of preclinical studies suggest that radiotheraphy in combination with VEGF targeting agents enhances the radiotherapeutic ratio (see reviews). The best way to incorporate VEGF inhibition strategies into current radiotherapy regimens remains unknown.

Because of the role that angiogenesis plays in the radiation response, the objective of this study was to determine whether VEGF Trap (Regeneron Pharmaceuticals, Tarrytown, NY), a potent anti-VEGF angiogenesis inhibitor that traps circulating VEGF in the bloodstream and in the extracellular space, would enhance radiation therapy in the human U87 glioblastoma (GBM) tumor model. Because GBM tumors are among the most radioresistant and vascular of neoplasms and are known to secrete high levels of VEGF, U87 GBM was deemed an appropriate model to assess the effects of VEGF Trap and radiation. It was hypothesized that inhibition of VEGF signaling by VEGF Trap would improve the human U87 glioblastoma model response to radiotherapy.

The administration of decoy soluble VEGF receptors has been found to be a very effective way to block the VEGF signaling pathways. VEGF Trap is a unique human fusion protein comprising portions of human VEGF rece-
as well as reduce the formation of malignant ascites.\textsuperscript{14, 21, 31}

Methods and Materials

Analysis of VEGF levels in U87 tumor cells in culture

U87 glioblastoma cells (American Type Culture Collection) were maintained in alpha MEM (Sigma-Aldrich, St. Louis, MO) with 10% fetal bovine serum (Atlanta Biologicals, Norcross, GA). U87 cells were irradiated at doses between 2 and 20 Gy in the presence or absence of 40 nM VEGF Trap and incubated for 48 h. Using a commercially available human VEGF immunoassay kit (R&D Systems, Minneapolis, MN), VEGF was assayed from culture supernatants.

Animal and tumor model

U87 cell suspensions (5 x 10^5 cells in 100 μL phosphate buffered saline) were implanted subcutaneously (SC) into the right hind limbs of athymic NCR Nu/Nu mice (Taconic Farms, Hudson, NY). A SC xenograft model was chosen to facilitate radiation dosing and ease of tumor measurements in the more than 200 mice measured in this study. Mice were not pretreated before tumor implantation. U87 tumors were allowed to grow for approximately 14 to 18 days until reaching an approximate diameter of 4 to 5 mm before treatment.

Drug and irradiation treatment

In an initial pilot study, VEGF Trap was administered at two doses, a high dose (25 mg/kg) or low dose (2.5 mg/kg), every 3 days, up to 3 weeks, with or without a single dose of radiation (10 Gy) given on Day 0. VEGF Trap was administered every 3 days because it has a half-life of 72 h in mouse serum (drug pharmacokinetics communicated by Regeneron). Drug was administered 2 h before radiation. When fractionated radiotherapy was used, VEGF Trap was combined at 2.5 mg/kg (low dose) or 10 mg/kg (intermediate dose) with fractionated radiotherapy (three fractions of 5 Gy each) on Days 0, 1, and 2. Scheduling of VEGF Trap was either 1 week before fractionated radiation and continuing for a period of 3 weeks, concurrent with radiation and continuing for a period of 3 weeks, or 3 days postradiation treatment and continuing for a period of 3 weeks. Thus, the total number of drug doses was constant for each schedule (see Fig. 1 for dose and irradiation scheduling protocol).

Irradiation was performed on anesthetized mice using an X-ray machine (Gulnary Medical, Bethel, CT) operating at 250 kV, 10 mA, with a 2-mm aluminum filtration. The effective photon energy was ~90 kV. Mouse were anesthetized with a combination of ketamine and acepromazine at a concentration of 75 mg/kg and 0.35 mg/kg, respectively. Each mouse was confined in a lead casing with its tumor-bearing leg extended through an opening on the side to allow the tumor to be irradiated locally. Radiation was administered as three daily fractions of 5 Gy each as described earlier.

Tumor size was measured 4 to 5 times per week after treatment by direct measurement with calipers and calculated by the formula (smallest diameter / 2) x (widest diameter / 2). Tumors were not allowed to grow beyond 2,000 mm^3 in accordance with Institutional Animal Care and Use Committee regulations.

Figure 1. Scheduling protocols for vascular endothelial growth factor (VEGF) Trap administration in combination with radiation (RT). VEGF Trap was given at 2.5, 10, or 25 mg/kg every 3 days in four schedules: (I) VEGF Trap + Single Dose RT (10 Gy); (II) VEGF Trap + Fractionated RT (3 x 5 Gy); (III) VEGF Trap given on Day 0 concurrent with RT (3 x 5 Gy); and continued up to 3 weeks; (IV) VEGF Trap given on Day 3 post RT (3 x 5 Gy) and continued up to 3 weeks. All three protocols received the same number of drug doses. Day 0 was always the start of radiation.
Effect of VEGF Trap and single dose radiation (10 Gy) on U87 tumor growth inhibition

Table 1 presents tumor growth data based on the mixed-effects linear regression analysis described in Methods and Materials, and Fig. 3 presents the original animal data. In this experiment, a low dose of VEGF Trap (2.5 mg/kg) initiated concurrently with a single dose of 10 Gy was compared with a 10x higher dose of VEGF Trap (25 mg/kg) plus 10 Gy. The six groups are compared in terms of average daily tumor growth and doubling time. It can be seen from Table 1 and Fig. 3 that both low-dose and high-dose VEGF Trap were effective inhibitors of daily percent increase in tumor volume (%Δ = 27% vs. 31% for 10 Gy alone and 15% and 5%, respectively, vs. 31% for controls, p < 0.001). Although low-dose VEGF Trap was not significantly better than 10-Gy treatment alone, the combination of low-dose VEGF Trap and 10 Gy slowed daily tumor growth (%Δ = 12% vs. 18% for 10 Gy alone and 55% for low VEGF Trap alone). Thus, a less than additive in vivo effect was observed, with the combination being less than additive in vivo for that particular dose of radiation. High-dose VEGF Trap, as a single treatment modality, was more efficacious in slowing daily percent increase in tumor volume (%Δ = 18% for 10 Gy). Its efficacy was improved by the addition of 10 Gy. This study...
Figure 3. Effect of vascular endothelial growth factor (VEGF) Trap combined with single-dose radiation (10 Gy) on tumor growth in U87GBM. Individual mouse data for six treatment groups (n = 10–12 animals per group). VEGF Trap was given at 2.5 or 25 mg/kg starting on Day 0, concurrent with radiation and continuing every 3 days for 3 weeks (see schedule 1, Fig. 1).
Figure 4. Effect of vascular endothelial growth factor (VEGF) Trap initiated before fractionated radiation (3 x 5 Gy) on tumor growth in U87 GBM. Individual mouse data for 6 treatment groups (n = 10–14 animals/group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day –7 and continuing every 3 days for 3 weeks (see schedule II, Fig. 2).
Figure 5. Effect of vascular endothelial growth factor (VEGF) Trap sequenced concurrent with fractionated radiation (3 x 5 Gy) on tumor Growth in U87 GBM. Individual mouse data for six treatment groups (n = 10–14 animals per group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day 0 and continuing every 3 days for 3 weeks (see schedule III, Fig. 3).
Figure 6. Effect of vascular endothelial growth factor (VEGF) Trap sequenced post-fractionated radiation (3 x 5 Gy) on tumor growth in U87 GBM. Individual mouse data for six treatment groups (n = 10–14 animals/group). VEGF Trap was given at 2.5 or 10 mg/kg starting on Day 3 and continuing every 3 days for 3 weeks (see schedule IV, Fig. 4).
suggests that low-dose VEGF Trap in combination with single-dose radiation has an enhanced effect on tumor cell kill. It was thought that this enhancement might be improved by varying dose and scheduling protocol. Additional studies were carried out in which low-dose VEGF Trap at 2.5 mg/kg was compared with an intermediate dose of 10 mg/kg (because VEGF Trap at 25 mg/kg appeared to have masked any additional benefit of radiation in enhancing tumor control) in combination with a more clinically relevant fractionated radiotherapy protocol. The results of these studies are reported in the following sections.

**Effect of VEGF Trap and fractionated radiation on U87 tumor growth inhibition**

VEGF Trap given before fractionated radiation: in this protocol, VEGF Trap was administered 7 days before radiation. The analyses allowed for separate tumor growth rates in the first and second periods (pretreatment: Days –7 to 0; postradiation: Days 0+) for the groups that received radiation. The study's main aim was to compare tumor growth rates across treatment groups in the latter period, when all treatments had been applied. Table 1 summarizes the results of the tumor growth modeling analyses during this main study phase, and Fig. 4 presents the original animal data. The low-dose VEGF Trap group (2.5 mg/kg every third day, starting at Day –7) demonstrated a reduction in daily percent increase in tumor volume (12% vs. 27% for control; p = 0.001) that was similar to the first single-dose radiation study, whereas the high-dose VEGF Trap group (10 mg/kg every third day, starting at Day –7) had an even stronger effect (7%) that, again, was similar in trend to the first study. In the radiation only group, tumor daily growth was slowed to 11% (p < 0.001 vs. control).

Although low-dose VEGF Trap was comparable to radiation alone (p = 0.59), the combination of low-dose VEGF Trap with radiation (7% average daily percent increase in tumor volume) was significantly better than either radiation alone (p = 0.036) or low-dose VEGF Trap alone (p = 0.33).

In summary, improved tumor control was seen when radiation (either single dose or fractionated doses) were combined with the lowest dose of VEGF Trap (2.5 mg/kg) used in these studies. Scheduling did not significantly affect the efficacy of combined therapy. The relative benefits of combined low-dose VEGF Trap plus fractionated radiation relative to radiation as judged by percent reduction in average daily increase in tumor volume were 36% for VEGF Trap given before radiation, 27% for VEGF Trap given postradiation: Table 2 summarizes the results of the tumor growth modeling analyses based on original animal data shown in Fig. 5. High-dose VEGF Trap was significantly better than radiation in reducing daily percent increase in tumor volume (8.5% vs. 16.1% for radiation, p = 0.001). The combination of high-dose VEGF Trap with radiation (12% average daily increase in tumor volume) was significantly better than radiation alone (p = 0.029) or low-dose VEGF Trap alone (p = 0.012). The combination of high-dose VEGF Trap (10 mg/kg) with radiation (7% average daily increase in tumor volume) was also significantly better than radiation alone (p = 0.001) but not high-dose VEGF Trap alone (p = 0.417).

**Table 1. Effect of VEGF Trap combined with single-dose radiation: Summary of tumor growth (Schedule I)**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>%Δ (95% CI)</th>
<th>T2x</th>
<th>p values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (human FC protein)</td>
<td>31.0 (27–35)</td>
<td>2.6</td>
<td></td>
</tr>
<tr>
<td>RT (10 Gy)</td>
<td>10.0 (15–21)</td>
<td>4.2</td>
<td>0.001 vs. control, 0.10 vs. VEGF Trap (low)</td>
</tr>
<tr>
<td>VEGF Trap (2.5 mg/kg)</td>
<td>15.0 (15–28)</td>
<td>6.9</td>
<td>0.001 vs. control, 0.10 vs. RT alone</td>
</tr>
<tr>
<td>VEGF Trap (10 mg/kg)</td>
<td>7.0 (4–9)</td>
<td>11.5</td>
<td>0.001 vs. control, 0.01 vs. RT alone, 0.001 vs. VEGF Trap (low)</td>
</tr>
<tr>
<td>VEGF Trap (2.5 mg/kg) + RT</td>
<td>12.0 (9–14)</td>
<td>6.3</td>
<td>0.001 vs. RT, 0.00 vs. VEGF Trap (low)</td>
</tr>
<tr>
<td>VEGF Trap (25 mg/kg) + RT</td>
<td>5.0 (2–7)</td>
<td>15.5</td>
<td>0.001 vs. RT, 0.417 vs. VEGF Trap (high), 0.96 vs. VEGF Trap (low) + RT</td>
</tr>
</tbody>
</table>

**Table 2. VEGF Trap initiated before fractionated radiation: Summary of tumor growth (Schedule II)**

<table>
<thead>
<tr>
<th>Treatment</th>
<th>%Δ (95% CI)</th>
<th>T2x</th>
<th>p values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (human FC protein)</td>
<td>27.0 (25–31)</td>
<td>5.0</td>
<td></td>
</tr>
<tr>
<td>RT (15 Gy)</td>
<td>11.0 (8–15)</td>
<td>6.5</td>
<td>0.001 vs. control, 0.09 vs. VEGF Trap (low), 0.027 vs. VEGF Trap (high)</td>
</tr>
<tr>
<td>VEGF Trap (2.5 mg/kg)</td>
<td>12.0 (10–15)</td>
<td>5.9</td>
<td>0.001 vs. control, 0.09 vs. RT</td>
</tr>
<tr>
<td>VEGF Trap (25 mg/kg)</td>
<td>7.0 (4–9)</td>
<td>11.1</td>
<td>0.001 vs. control, 0.027 vs. RT, 0.00 vs. VEGF Trap (low)</td>
</tr>
<tr>
<td>VEGF Trap (low) + RT</td>
<td>7.0 (4–9)</td>
<td>10.6</td>
<td>0.04 vs. RT, 0.004 vs. VEGF Trap (low)</td>
</tr>
<tr>
<td>VEGF Trap (high) + RT</td>
<td>5.0 (2–7)</td>
<td>15.3</td>
<td>0.002 vs. RT, 0.33 vs. VEGF Trap (high)</td>
</tr>
</tbody>
</table>

Abbreviations: %Δ = daily% increase in tumor volume; CI = confidence interval; RT = radiation; VEGF = vascular endothelial growth factor; T2x = average doubling time for tumor volume (in days).
between 900 and 1600 mm³. The percent of metabolically inactive tumor volume (as measured by FDG uptake) was measured as a function of tumor volume and averaged over a range of tumor volumes and low dose VEGF Trap alone (starting at Day 0) for 3 weeks. Tumor volume (mm³) and days following start of treatment are indicated. Because of the difficulty in matching tumor volumes and time after treatment, the percent of metabolically inactive tumor volume (as measured by FDG uptake) was measured as a function of tumor volume and averaged over a range of tumor volumes and low dose VEGF Trap alone (p = 0.29). However, there was a significant difference in MVD between low dose VEGF Trap–treated with radiation and low-dose VEGF Trap alone (p = 0.01, Fig. 8).

18-fluorodeoxyglucose–PET imaging of VEGF Trap–treated tumors

Figure 9a illustrates a series of images from a representative, untreated mouse. Figure 9b represents a series of images from a representative mouse treated with VEGF Trap dosed at or 10 mg/kg every 3 days (starting at Day 0) for 3 weeks. Tumor volume (mm³) and days following start of treatment are indicated. Because of the difficulty in matching tumor volumes and time after treatment, the percent of metabolically inactive tumor volume (as measured by FDG uptake) was measured as a function of tumor volume and averaged over a range of tumor volumes (starting at Day 0) for 3 weeks. Tumor volume (mm³) and days following start of treatment are indicated. Because of the difficulty in matching tumor volumes and time after treatment, the percent of metabolically inactive tumor volume (as measured by FDG uptake) was measured as a function of tumor volume and averaged over a range of tumor volumes and low dose VEGF Trap alone (p = 0.01, Fig. 8).

Table 3. Trap sequenced concurrently with radiation: Summary of tumor growth (Schedule III)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>%Δ (95% CI)</th>
<th>T2x</th>
<th>p values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (human PC)</td>
<td>27.0 (26–30)</td>
<td>2.9</td>
<td></td>
</tr>
<tr>
<td>RT (3 x 5 Gy)</td>
<td>16.0 (15–19)</td>
<td>4.6</td>
<td>0.001 vs. control, 0.729 vs. VEGF Trap (low), 0.001 vs. VEGF Trap (high)</td>
</tr>
<tr>
<td>VEGF Trap (2.5 mg/kg)</td>
<td>17.0 (16–19)</td>
<td>4.5</td>
<td>0.001 vs. control, 0.729 vs. RT alone</td>
</tr>
<tr>
<td>VEGF Trap (10 mg/kg)</td>
<td>8.3 (6–13)</td>
<td>6.5</td>
<td>0.001 vs. control, 0.001 vs. RT alone, 0.001 vs. VEGF Trap (low)</td>
</tr>
<tr>
<td>VEGF Trap (low) + RT</td>
<td>12.0 (9–15)</td>
<td>6.5</td>
<td>0.020 vs. RT, 0.008 vs. VEGF Trap (low)</td>
</tr>
<tr>
<td>VEGF Trap (high) + RT</td>
<td>7.0 (5–9)</td>
<td>10.3</td>
<td>0.001 vs. RAD, 0.002 vs. VEGF Trap (high), 0.014 vs. VEGF Trap (low)</td>
</tr>
</tbody>
</table>

Discussion

This work demonstrated that VEGF Trap alone is an effective dose-dependent inhibitor of tumor growth in U87 GBM. These findings agreed with previous studies of VEGF Trap in other preclinical animal models demonstrating efficacy in halting angiogenesis and shrinking tumors. Because VEGF Trap was very potent by itself and could have potentially masked any additional benefits of radiation, both low-dose and high-dose scheduling of the drug were used with radiotherapy. In all scheduling protocols that were investigated, the combination of low-dose VEGF Trap with radiation was significantly better than either treatment modality alone. On the other hand, high-dose VEGF Trap was significantly better than radiation alone and therefore masked any additional benefit that may have resulted from combination therapy. The benefit of combined treatment with low VEGF Trap and radiation relative to radiation alone was not influenced by scheduling protocol. This result was in contrast to earlier work demonstrating improved radiation response when a VEGF blocker, DC101, was given 4 to 6 days before radiotherapy. This earlier work suggested that tumor vasculature normalization occurred during pretreatment with the VEGF blocker, a process in which pruning of immature and insufficient blood vessels occurs leading to improved tumor perfusion and oxygenation and improved radiation response. The current observations may reflect the absence of a normalization effect by VEGF Trap on U87 GBM vasculature or a missed window of opportunity for normalization because of the particular protocols used in this work. Because it is not known how tumor oxygenation levels may have varied throughout the course of combined treatment with VEGF Trap and radiation, additional studies are warranted to resolve the issue of normalization. The observation that scheduling did not have an impact on efficacy of combined treatment with VEGF Trap and radiation in this study is also in contrast to recent studies in which VEGF blockade was obtained either by a VEGF receptor 2 tyrosine kinase inhibitor, ZD6474, or indirectly by a VEGF receptor 2 tyrosine kinase inhibitor, ZD6474.

Table 4. VEGF Trap sequenced post–fractionated radiation: Summary of tumor growth (Schedule IV)

<table>
<thead>
<tr>
<th>Treatment</th>
<th>%Δ (95% CI)</th>
<th>T2x</th>
<th>p values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (human PC)</td>
<td>31.3 (28–35)</td>
<td>2.5</td>
<td></td>
</tr>
<tr>
<td>RT (3 x 5 Gy)</td>
<td>15.0 (13–17)</td>
<td>5.1</td>
<td>0.001 vs. control, 0.460 vs. VEGF Trap (low), 0.001 vs. VEGF Trap (high)</td>
</tr>
<tr>
<td>VEGF Trap (2.5 mg/kg)</td>
<td>16.0 (15–19)</td>
<td>4.7</td>
<td>0.001 vs. control, 0.460 vs. RT alone</td>
</tr>
<tr>
<td>VEGF Trap (10 mg/kg)</td>
<td>8.0 (5–10)</td>
<td>9.2</td>
<td>0.001 vs. control, 0.001 vs. RT alone, 0.001 vs. VEGF Trap (low)</td>
</tr>
<tr>
<td>VEGF Trap (low) + RT</td>
<td>10.0 (7–12)</td>
<td>7.4</td>
<td>0.014 vs. RT, 0.001 vs. VEGF Trap (low)</td>
</tr>
<tr>
<td>VEGF Trap (high) + RT</td>
<td>5.3 (3–8)</td>
<td>12.8</td>
<td>0.001 vs. RT, 0.147 vs. VEGF Trap (high), 0.015 vs. VEGF Trap (low)</td>
</tr>
</tbody>
</table>

Abbreviations: %Δ daily increase in tumor volume; CI: confidence interval; RT: radiation; VEGF: vascular endothelial growth factor; T2x: average doubling time for tumor volume (in days).
HIF-1 alpha blockade of VEGF secretion. In both these studies, optimal antitumor efficacy was obtained when VEGF blockers were sequenced following radiation2, 33. These studies suggested that prolonged suppression of radiation-induced angiogenesis accounts for enhanced efficacy of combined treatments with angiogenesis blockade and radiation. However, it is not clearly understood why there is a difference in the impact of scheduling among these agents.

This work is encouraging in that it demonstrates for the first time a benefit in combining VEGF Trap with ionizing radiation in a highly resistant GBM tumor model. VEGF Trap is a unique human fusion protein with very potent binding affinity for VEGF A isoforms as well as placental growth factor (PIGF) and is currently in clinical trials. Its affinity for VEGF is potentially 100- to 1,000-fold higher than existing VEGF monoclonal antibodies such as bevacizumab34. This high-affinity blockade of VEGF differentiates VEGF Trap from other anti-VEGF strategies and therefore gives this drug the potential to enhance combination modality treatment with lower dosing.

Mechanisms of enhanced U87 tumor control by combined therapy with VEGF Trap and radiation most likely include inhibition of radiation-induced angiogenesis by VEGF Trap sequestration of circulating VEGF in the bloodstream and in the extracellular tumor space resulting from radiation-induced secretion. Indeed, in this study, a radiation-dose-dependent increase in VEGF secretion by U87 glioblastoma cells was observed and excess VEGF was bound in the presence of VEGF Trap. In addition, immunohistochemical findings indicated a reduction in MVD 3 weeks following treatment with VEGF Trap and radiation. Inhibition of radiation-induced angiogenesis was also observed indirectly through FDG–PET imaging, which revealed an increase in metabolically inactive tumor tissue after VEGF Trap treatment, possibly arising from the induction of tumor necrosis or apoptosis in the presence of angiogenesis inhibition. It is also of interest that in this study, a brief period of fractionation...
ated radiotherapy with VEGF Trap resulted in tumor growth retardation but not remission. The lack of remission is probably related to continued production of VEGF after removal of drug and radiation and points to the need for chronic therapy with VEGF Trap, which is in agreement with what has been observed for the transient effects of other antiangiogenic agents on tumor growth22.

In conclusion, these studies demonstrate that the combination of low-dose VEGF Trap and radiation is clearly better than radiation alone in a U87 subcutaneous xenograft model. Although high doses of VEGF Trap alone are highly efficacious, it is unclear whether such high doses can be used clinically without incurring normal tissue toxicities. Thus, information on lower doses of VEGF Trap and ionizing radiation is of clinical relevance.

It is understood that the SC xenograft model used in this study has shortcomings in that ectopic tumors implanted SC in the hind limb of animals do not duplicate the vascular microenvironment of orthotopic brain implants23, 35. However, the use of SC xenografts is the standard approach for xenograft studies with radiation. In addition, human xenografts in immunocompromised nude mice, whether they be ectopic or orthotopic, both have deficiencies in that they can only approximate the human patient situation and seldom reflect accurately the glioblastoma multiforme histopathology seen in patients. This study is encouraging in that it demonstrates for the first time a benefit in combining VEGF Trap with ionizing radiation and warrants further investigations both preclinically and clinically.

References